This argument can be further validated by several recent meta‐analyses based on clinical studies, which unequivocally highlighted the strong prognostic capability of M‐protein reduction for long‐term survival in MM patients [11, 12, 13]. The gene discussed is MYOM2; the disease is Miyoshi myopathy.